.png)
TB006 Infusion
Pioneer Hope for Alzheimer’s Recovery
$6,500.00 per infusion (FDA-approved study; qualification required)
TB006 is an experimental intravenous therapy delivering a 4,000 mg monoclonal antibody targeting Galectin-3 to reduce amyloid plaque and neuroinflammation in Alzheimer’s disease. Administered every 28 days, it offers a targeted, disease-modifying approach to slow cognitive decline and improve function.
Why It Matters
As part of an FDA-approved study, TB006 represents a groundbreaking approach to Alzheimer’s treatment. By addressing molecular drivers, it offers hope for slowing or reversing cognitive decline, improving memory, and enhancing daily functioning for patients with mild to severe Alzheimer’s.
Key Benefits
Cognitive Support: May slow or reverse cognitive decline.
Targeted Therapy: Neutralizes Galectin-3 to address Alzheimer’s drivers.
Hope for Recovery: Potential to improve memory and daily functioning.
During a 1-hour infusion every 28 days, you’ll relax in our comfortable medical setting while our team administers the dose via IV. Our experts monitor your safety and comfort. As a trial participant, you’ll receive ongoing assessments to track progress. Qualification is required.
Especially Important For
Patients with mild to severe Alzheimer’s disease.
Individuals seeking innovative, research-backed treatments.
Those eligible for the FDA-approved clinical trial.
See all in-center services below:
Join the fight against Alzheimer’s with TB006. Contact us to explore eligibility and take a step toward hope!